The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural Mesothelioma After Multimodality Therapy.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ analysis
Cisplatin
/ administration & dosage
Combined Modality Therapy
/ methods
Female
Humans
Immunohistochemistry
Lung Neoplasms
/ enzymology
Male
Mesothelioma
/ enzymology
Mesothelioma, Malignant
Middle Aged
Mitogen-Activated Protein Kinase 1
/ analysis
Molecular Targeted Therapy
Pemetrexed
/ administration & dosage
Pleural Neoplasms
/ enzymology
Pneumonectomy
Prognosis
Protein Serine-Threonine Kinases
/ analysis
TOR Serine-Threonine Kinases
/ analysis
extrapleural pneumonectomy
mTOR signal pathway
malignant pleural mesothelioma
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
30
08
2019
revised:
20
09
2019
accepted:
25
09
2019
entrez:
10
11
2019
pubmed:
11
11
2019
medline:
15
11
2019
Statut:
ppublish
Résumé
We performed multimodality therapy comprising preoperative chemotherapy, extrapleural pneumonectomy (EPP), and radiation therapy for patients with malignant pleural mesothelioma (MPM). Although multimodality therapy resulted in good prognosis, further improvement is required. Therefore, herein, we analysed the prognostic factors using surgical specimens and searched for suitable molecular targets to improve the prognosis after multidisciplinary treatment. Forty-six patients with MPM underwent multimodality therapy. Paraffin-embedded surgical samples were used for immunohistochemistry to evaluate the expression of phosphorylated (p-) AKT, extracellular signal-regulated kinase (ERK), mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK), eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and S6 ribosomal protein (S6RP). On univariate and multivariate analyses, significant differences were observed according to the histological type, pathological stage, and p-mTOR expression rate. The prognosis of MPM is affected by p-mTOR expression, suggesting that molecular-targeted treatment might be used during multimodal therapy for MPM.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
We performed multimodality therapy comprising preoperative chemotherapy, extrapleural pneumonectomy (EPP), and radiation therapy for patients with malignant pleural mesothelioma (MPM). Although multimodality therapy resulted in good prognosis, further improvement is required. Therefore, herein, we analysed the prognostic factors using surgical specimens and searched for suitable molecular targets to improve the prognosis after multidisciplinary treatment.
PATIENTS AND METHODS
METHODS
Forty-six patients with MPM underwent multimodality therapy. Paraffin-embedded surgical samples were used for immunohistochemistry to evaluate the expression of phosphorylated (p-) AKT, extracellular signal-regulated kinase (ERK), mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK), eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and S6 ribosomal protein (S6RP).
RESULTS
RESULTS
On univariate and multivariate analyses, significant differences were observed according to the histological type, pathological stage, and p-mTOR expression rate.
CONCLUSION
CONCLUSIONS
The prognosis of MPM is affected by p-mTOR expression, suggesting that molecular-targeted treatment might be used during multimodal therapy for MPM.
Identifiants
pubmed: 31704853
pii: 39/11/6241
doi: 10.21873/anticanres.13833
doi:
Substances chimiques
Biomarkers, Tumor
0
Pemetrexed
04Q9AIZ7NO
MTOR protein, human
EC 2.7.1.1
Protein Serine-Threonine Kinases
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
MAPK1 protein, human
EC 2.7.11.24
Mitogen-Activated Protein Kinase 1
EC 2.7.11.24
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6241-6247Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.